Search research articles
Contact Us
Filters
Showing results (21-30 of 33) with videos related to
Page
of 4
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
April 25, 2013
A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer
J A Davidson, I Cromwell, S L Ellard, et al.
Breast Cancer Research and Treatment
|
April 27, 2016
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer
Daniel Rayson, Sasha Lupichuk, Kylea Potvin, et al.
Breast Cancer Research and Treatment
|
October 14, 2017
A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213
V Bernstein, S L Ellard, S F Dent, et al.
Cancer Medicine
|
December 18, 2021
What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
Sara Pizzamiglio, Giulia Cosentino, Chiara M Ciniselli, et al.
The Lancet. Oncology
|
November 16, 2019
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
Daniel J Khalaf, Matti Annala, Sinja Taavitsainen, et al.
Plos One
|
July 15, 2011
Identification of novel therapeutic targets in microdissected clear cell ovarian cancers
Michael P Stany, Vinod Vathipadiekal, Laurent Ozbun, et al.
Clinical Genitourinary Cancer
|
May 7, 2019
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205
Sebastien J Hotte, Kim N Chi, Anthony M Joshua, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study
Nicholas C Turner, Judith Balmaña, Coralie Poncet, et al.
Lancet (London, England)
|
January 24, 2021
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
Stephanie Lheureux, Mihaela C Cristea, Jeffrey P Bruce, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 9, 2014
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer
Elizabeth Maunsell, Paul E Goss, Rowan T Chlebowski, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 33) with videos related to
Sort By:
Page
of 4
European Journal of Cancer (Oxford, England : 1990)
|
April 25, 2013
A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer
J A Davidson, I Cromwell, S L Ellard, et al.
Breast Cancer Research and Treatment
|
April 27, 2016
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer
Daniel Rayson, Sasha Lupichuk, Kylea Potvin, et al.
Breast Cancer Research and Treatment
|
October 14, 2017
A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213
V Bernstein, S L Ellard, S F Dent, et al.
Cancer Medicine
|
December 18, 2021
What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
Sara Pizzamiglio, Giulia Cosentino, Chiara M Ciniselli, et al.
The Lancet. Oncology
|
November 16, 2019
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
Daniel J Khalaf, Matti Annala, Sinja Taavitsainen, et al.
Plos One
|
July 15, 2011
Identification of novel therapeutic targets in microdissected clear cell ovarian cancers
Michael P Stany, Vinod Vathipadiekal, Laurent Ozbun, et al.
Clinical Genitourinary Cancer
|
May 7, 2019
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205
Sebastien J Hotte, Kim N Chi, Anthony M Joshua, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study
Nicholas C Turner, Judith Balmaña, Coralie Poncet, et al.
Lancet (London, England)
|
January 24, 2021
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
Stephanie Lheureux, Mihaela C Cristea, Jeffrey P Bruce, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 9, 2014
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer
Elizabeth Maunsell, Paul E Goss, Rowan T Chlebowski, et al.
Page
of 4